Studies have indicated that bevacizumab combined with targeted therapy can inhibit tumor progression and prolong the survival time of NSCLC patients, and vascular endothelial growth factor is correlated with the EGFR pathway, stage II (JO25567),[15] and stage III (NEJ026),[16] and clinical trials have shown that bevacizumab combined with EGFR-TKIs can prolong the PFS time of patients and delay the drug resistance time of EGFR-TKIs. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.